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ABSTRACT
Introduction: Anti-staphylococcal penicillins
are generally accepted as first-line therapy for
methicillin-susceptible Staphylococcus aureus
(MSSA) bacteremia, but their use may be limited
by interstitial nephritis and acute kidney injury.
Alternatives include first-generation cephalos-
porins including cefazolin.
Methods: We conducted a retrospective cohort
study to compare adverse effects and clinical
outcomes among patients with MSSA bac-
teremia treated with cefazolin or nafcillin. The
primary endpoint was acute kidney injury
(AKI), defined as a 0.3 mg/dL or 50% increase
from baseline.
Results: Incidence of AKI was 27/82 (33%)
versus 9/68 (13%) (p = 0.007) in the nafcillin
and cefazolin arms, respectively. After adjusting
for endocarditis and intensive care unit admis-
sion in multivariate logistic regression, nafcillin
was an independent predictor of AKI [adj odds
ratio (OR) = 2.74; 95% (CI) 1.1–6.6]. Patients
who experienced AKI were more likely to have a
prolonged intensive care unit stay.
Conclusion: Risk of nephrotoxicity is increased
with nafcillin comparedwith cefazolin. Cefazolin
shouldconsideredasa saferalternative tonafcillin
for select patients with MSSA bacteremia.
Keywords: Cost-effective; Methicillin-
susceptible staphylococcus aureus (MSSA);
Nephrotoxicity
INTRODUCTION
Staphylococcus aureus is a pathogen that is associ-
ated with high healthcare costs and mortality.
When compared to other organisms causing
bacteremia, it was associated with a greater med-
ian length of stay and total treatment cost [1].
Although the incidence ofmethicillin-resistant S.
aureus (MRSA) infections are rising, methi-
cillin-susceptible S. aureus (MSSA) bloodstream
infections (BSI) are still prevalent [2]. For the
treatment ofMSSA infections, use of beta-lactams
antibiotics compared to vancomycin therapy is
associated with about a 35% lower rate of
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mortality [3, 4]. Therefore, beta-lactams are
known to be the treatment of choice for this
infection.However, what is notwell established is
which beta-lactam is preferred.
Comparative studies of MSSA bacteremia
suggest no overall difference in clinical success,
mortality, or length of stay between
anti-staphylococcal penicillins and cefazolin
[5–9]. However, recent literature suggests that
cefazolin may offer safety advantages. Nafcillin
has been associated with a higher rate of pre-
mature antibiotic discontinuation, 18–33.8%
due to adverse effects, compared with 2–6.7%
for cefazolin. It has also been associated with a
higher incidence of nephrotoxicity of 11.4–15%
and cefazolin with 0–3.4% [10, 11]. Generaliz-
ability of the previous literature may be limited
by the study setting of outpatient versus inpa-
tient, definitions utilized, and early beta-lactam
discontinuation. Definitions of AKI throughout
the literature vary in sensitivity; however, if
improving safety through early identification is
the endpoint of interest, a more conservative
definition is preferred [12].
Based on the literature to date, it appears
that cefazolin may be a safer alternative [10, 11].
In addition, the average wholesale price of naf-
cillin for 1 day of treatment is approximately
US$162 compared with less than $8 per day for
cefazolin. Using a mean duration of treatment
for MSSA bacteremia of 20 days, from the liter-
ature, the total medication cost would be $3400
with nafcillin and $166 for cefazolin [11]. A
comprehensive economic analysis incorporat-
ing drug costs, toxicity, and cost of care has yet
to be published. The purpose of this study was
to evaluate the outcomes of infection, safety
and economic impact of using cefazolin versus
nafcillin in patients with MSSA BSI. We
hypothesized that cefazolin would be associated
with less nephrotoxicity and would be a more
cost-effective alternative than nafcillin, but
would have similar clinical outcomes.
METHODS
This retrospective cohort study was conducted
at the Henry Ford Health System, a four-hospi-
tal health system in Detroit, Michigan, and
surrounding areas. This study was approved by
the Henry Ford Hospital institutional review
board. This article does not contain any new
studies with human or animal subjects per-
formed by any of the authors. Patients were
eligible for inclusion if they were C18 years old
with at least one positive MSSA blood culture
from November 2013 to October 2015 and
received cefazolin or nafcillin for C72 h. If
patients received both nafcillin and cefazolin,
then they were included in the arm corre-
sponding to initial beta-lactam received C72 h.
Patients were excluded if they had evidence of
pre-existing renal dysfunction indicated by a
serum creatinine (SCr)[2 mg/dL, any form of
renal replacement therapy, or if meningitis was
the suspected or confirmed source.
The primary outcome was the incidence of
nephrotoxicity defined as an increase in SCr
from baseline C0.3 mg/dL within 48 h, or any
50% increase as assessed by blinded adjudica-
tion [12]. Clinical failure was defined as all-
cause mortality at 30 days, a recurrence of MSSA
infection within 60 days of discharge, and
microbiologic failure. Microbiologic failure was
defined as blood cultures growing MSSA for
[7 days from the start of initial beta-lactam
therapy. Clinical success was determined if all
components of the clinical failure definition
were not met. In-hospital mortality deemed to
be related to the MSSA infection included
patients with blood cultures still positive or
febrile on the day of death. Data was collected
from the electronic medical record using a
standardized case report form, and included
patient demographics, comorbid conditions,
risk factors for AKI, infection, and treatment
characteristics.
Resource utilization measures included total
length of stay (LOS), LOS in the intensive care
unit, average wholesale price (AWP), and overall
estimated cost of hospital stay. The health sys-
tem’s average cost per day in an intensive care
unit and general practice unit according to
American Hospital Association data and AWP
were used for the analytical model.
IBM SPSS v.21 (Chicago, IL, USA) was utilized
for statistical analysis. Categorical variables
were compared with Pearson Chi square tests
and continuous variables with Mann–Whitney
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U. Assuming an incidence of AKI of 30% in the
nafcillin group, approximately 75 patients were
required in each group to detect a difference of
20% in AKI with 80% power with an alpha-level
of 0.05 [13]. A multivariable logistic regression
analysis was used to evaluate the effect of naf-
cillin on nephrotoxicity after adjustment for
confounding variables. Variables were consid-
ered for the regression analysis if p values were
\0.2 in the univariate analysis or considered
clinically relevant. A decision analysis was used
to assess the most cost-effective treatment using
TreeAge software (Williamstown, MA, USA).
RESULTS
Of the 343 patients identified to have at least
one positive culture for MSSA during the study
period, a total of 186 were excluded from anal-
ysis, while 82 patients were included in the
nafcillin group and 75 patients in the cefazolin
group. An additional 8 patients were excluded
from the clinically evaluable population due to
AKI at the time of beta-lactam initiation (Fig-
ure S1). Table 1 highlights the differences in
baseline characteristics including male sex
(p = 0.003), age (p\0.001), and history of
penicillin allergy documented in
chart (p = 0.006). Table S1 provides additional
details of selected patient and treatment
characteristics.
The primary endpoint, incidence of AKI, was
26/81 (32%) versus 9/68 (13%) (p = 0.007), in
the nafcillin and cefazolin arms, respectively.
AKI with 50% increase in baseline creatinine
was experienced by 21/81 (25.9%) in the naf-
cillin and 7/68 (10.3%) in the cefazolin arms
(p = 0.015). In multivariable logistic regression,
nafcillin was an independent predictor of AKI
[adj odds ratio (OR) = 2.74; 95% (CI), 1.1–6.6]
after adjusting for endocarditis and stay in an
intensive care unit (Table 2). Additional vari-
ables thought to be clinically relevant but were
not different at baseline between the two groups
included: vancomycin [4 g per day prior to
initial beta-lactam, concomitant use of [1
additional nephrotoxin (vasopressors, loop
diuretics, aminoglycosides or vancomycin), and
PITT bacteremia score C4. The probability of
experiencing AKI increased with nafcillin com-
pared with cefazolin as the duration of treat-
ment increased (p = 0.011) and is demonstrated
by Fig. 1. Nine patients (11%) initially treated
with nafcillin were switched to cefazolin ther-
apy after 72 h due to nephrotoxicity, compared
with no switches in the cefazolin arm
(p = 0.005).
The median duration of vancomycin therapy
prior to switch to initial beta-lactam was 3 days
for each group (p = 0.783). Treatment failure
was identified in 17.6% of patients treated with
cefazolin and 13.6% for nafcillin (p = 0.494).
Treatment success was determined in 82.4%
and 86.4% in the cefazolin and nafcillin arms,
respectively. All-cause 30 day mortality was rare
and was not different between the two treat-
ment groups (6% for cefazolin vs. 5% for naf-
cillin, p = 0.538). Clinical failure secondary to
recurrent infection was determined in 1 of 68
(1.5%) for cefazolin and 2 of 81 (2.5%) in the
nafcillin arm (p = 0.666). In a subgroup analysis
of endocarditis patients, overall clinical failure
was experience in 4/11 (36.4%) of cefazolin
patients and 4/22 (18.2%) of nafcillin patients.
The incidence of additional adverse events for
cefazolin versus nafcillin were: Clostridium dif-
ficile 0% versus 6.3% (p = 0.036), neutropenia
2.5% versus 2.9% (p = 0.869), increased liver
function tests to greater than 3 times the upper
limit of normal 2% versus 9.9% (p = 0.032) and
drug rash 4.4% versus 4.9% (p = 0.88).
Overall length of stay was similar between
the two groups: 12 days [10–14] for cefazolin
and 14 days, [11–15] for nafcillin (p = 0.467).
Patients with endocarditis had a longer dura-
tion of bacteremia, 3 days [2–5], compared with
those patients who did not have endocarditis,
2 days [2, 3] (p = 0.028). For patients who
experienced AKI compared with those who did
not have AKI, they were more likely to have an
increased length of stay in the intensive care
unit 14 versus 10 days respectively. When
comparing drug costs alone for patients who
experienced AKI, they were $2271 for nafcillin
versus $75 for cefazolin. The decision tree is
described in Fig. 2, which shows that, when
cefazolin is used for MSSA bacteremia, there is a
96% chance of clinical success and an estimated
total cost of $16,059 compared with 83% and
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Table 1 Patient, clinical characteristics, concomitant medications of the clinically evaluable population
Covariate Cefazolin (n5 68) Nafcillin (n 5 81) p value
Male, n (%) 23 (33.8) 47 (58) 0.003
Age, median [IQR] 65 [61–68] 54 [51–58] \0.001
Suspected source, n (%)
Bone and joint 13 (19.1) 20 (24.7) 0.414
Endocarditis 11 (16.2) 22 (27.2) 0.108
Genitourinary tract 4 (5.9) 7 (8.7) 0.512
Skin and soft tissue 16 (23.5) 16 (19.8) 0.576
Other 6 (8.8) 11 (13.6) 0.363
Comorbidities, n (%)
Diabetes 33 (44) 29 (35.4) 0.269
Hypertension 51 (68) 49 (59.8) 0.283
Malignancy 20 (26.7) 17 (20.7) 0.381
IV drug users 7 (9.3) 16 (19.5) 0.072
Baseline SCr (mg/dL), median [IQR] 0.93 [0.7–1.29] 0.88 [0.74–1.03] 0.242
PITT bacteremia score C4, n (%) 7 (9.4) 13 (15.9) 0.221
Concomitant nephrotoxins, n (%)
Acyclovir 5 (7.4) 3 (3.7) 0.325
Aminoglycosides 5 (7.4) 10 (12.3) 0.313
Loop diuretics 25 (36.8) 25 (30.9) 0.447
Vancomycin 1 (1.5) 2 (2.5) 0.666
Vasopressor 2 (2.9) 8 (9.9) 0.092
History of penicillin allergy 18 (24) 6 (7.3) 0.006
Table 2 Univariate and multivariate model of nephrotoxicity
Predictor of nephrotoxicity Crude OR (95% CI) p value Adjusted OR (95% CI) p value
Nafcillin 3.1 (1.3–7.2) 0.007 2.7 (1.1–6.6) 0.025
Endocarditis 3.3 (1.4–7.7) 0.004 2.8 (1.2–6.8) 0.01
ICU at onset of infection 3.3 (1.5–7.3) 0.003 2.9 (1.3–6.8) 0.022
PITT bacteremia score C4 0.85 (0.3–2.8) 0.788 Not tested –
[1 Concomitant Nephrotoxina 1.03 (0.5–2.2) 0.006 Not tested –
Vancomycin[4 g per day prior to switch 0.79 (0.2–3.0) 0.737 Not tested –
a Concomitant nephrotoxin includes one of the following: acyclovir, aminoglycoside, loop diuretic, vancomycin, or
vasopressor
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$28,195, respectively, for nafcillin. The incre-
mental cost-effectiveness ratio could not be
calculated as cefazolin was dominant.
DISCUSSION
Since anti-staphylococcal penicillins and
first-generation cephalosporin agents are recom-
mended as first-line treatment options for MSSA
bacteremia, it is important to identify differences
among the agents in terms of their safety and cost
of therapy. Previously, when nafcillin and cefa-
zolinwere evaluated in the outpatient setting, the
incidence of renal impairment was found in
11.4% in nafcillin and 3.4% of cefazolin patients
[10]. In the inpatient setting, an increase in serum
creatinine levels C1.5 times baseline occurred
more commonly with nafcillin than with oxa-
cillin (18% vs. 6%; p = 0.03). Additionally, naf-
cillin had a higher incidence of discontinuation
due to nephrotoxicity compared to oxacillin
(9.4% vs. 0%, p = 0.007) [11]. The present study
confirms this prior literature and suggests that
first-generation cephalosporins appear to have a
more favorable side effect profile due to less
nephrotoxicity compared with nafcillin therapy,
and are more cost-effective. The statistical associ-
ation was consistently observed using a nephro-
toxicity definition of 0.3 mg/dL increase within
48 h and using any 50% increase. We identified
nephrotoxicity in 32% (nafcillin) and 13% (cefa-
zolin) of patients using the more sensitive defini-
tion, and26%and10%, respectively, usingamore
traditional definition. This incidence of AKI is
greater than previous studies. This may be due to
differences in the patient populations studied,
including the severity of illness and proportion of
patients with endocarditis in our study.
Another patient focused outcome that we
evaluated in our study was length of stay. The
length of stay was numerically higher in
patients on nafcillin at 14 days compared to
12 days for cefazolin; however, as this was not
our primary endpoint, this study was not pow-
ered to detect a difference. Endocarditis as the
Fig. 1 Time to nephrotoxicity stratified by cefazolin or
nafcillin
Fig. 2 Decision tree comparing cefazolin and nafcillin for the treatment of MSSA, its impact on nephrotoxicity and clinical
success
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source of infection, comorbidities, and devel-
opment of acute kidney injury are among the
many factors that could contribute to an
increased length of stay. Data from this study
may help to improve safety monitoring of
beta-lactams for MSSA bacteremia. Early iden-
tification of acute kidney injury may ultimately
reduce length of stay.
Although there is a lower average wholesale
price for cefazolin versus oxacillin treatment
($150 per day) or nafcillin ($166 per day), drug
acquisition cost is a minor component on
overall cost burden. Patients who experienced
AKI in our study had a longer length of stay in
the intensive care unit, contributing to a larger
difference in overall costs between the agents.
After adjusting for a diagnosis of endocarditis
and ICU admission, nafcillin was still indepen-
dently associated with AKI. Use of cefazolin for
patients with MSSA endocarditis is somewhat
controversial and generally reserved for patients
with penicillin allergy [14]. This recommenda-
tion stems from evidence suggesting clinical
failures due to an inoculum effect [15]. Our
subgroup of 33 patients with endocarditis sup-
port this recommendation, as 4/11 (36.4%) of
cefazolin patients and 4/22 (18.2%) of nafcillin
patients experienced clinical failure. However,
3/11 (27.3%) of cefazolin patients and 11/22
(50%) of nafcillin patients with endocarditis
experienced AKI.
This study had several limitations, including
the retrospective design and single health-sys-
tem. The primary endpoint of AKI was derived
from previous literature but may be too sensi-
tive. However, the improved safety with cefa-
zolin was also demonstrated with a more
conservative definition of 50% increase from
baseline. Some selection bias is likely present, as
patients who experienced AKI prior to initiation
of beta-lactam therapy were more likely to
receive cefazolin. Urine eosinophils were only
collected from three of the patients who expe-
rienced AKI and there were no kidney biopsies
obtained to classify the type of AKI that occur-
red. Therefore, there is no way of knowing if the
AKI was acute interstitial nephritis or due to
other causes. Beta-lactamase typing was not
performed, as it is not a standard of care and
was not available at our institution. No
differences were found in concomitant
nephrotoxins between the two groups; how-
ever, not all nephrotoxins were evaluated.
Despite these limitations, the existing body of
literature suggests that cefazolin may be the
preferred beta-lactam in patients with MSSA
bacteremia without central nervous system
involvement. In patients with endocarditis, a
careful risk–benefit evaluation is indicated and
future studies should be carried out to evaluate
these differences prospectively.
CONCLUSION
In conclusion, risk of nephrotoxicity is
increased with nafcillin compared with cefa-
zolin. Considering the safety profile and acqui-
sition cost of cefazolin, it may be considered as
a preferred therapy to nafcillin for patients with
MSSA bacteremia without endocarditis or cen-
tral nervous system involvement.
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